Thai Huu Ho MD PhD
Genitourinary Oncology, Hematologic Oncology
Associate Professor, Internal Medicine, Mayo Medical School
Join to view full profile
13400 E Shea Blvd# MayoScottsdale, AZ 85259
Phone+1 480-301-8335
Fax+1 480-301-4675
Dr. Ho is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Clinical Expertise
- Alternative Splicing, RNA Splicing, Cell Line, Histone Code, Kidney Neoplasms, Renal cell carcinoma, Therapeutics, Urologic oncology, Hematologic oncology, General medical oncology, Urethral cancer
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2009 - 2012
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 2006 - 2009
Baylor College of MedicineClass of 2006
Certifications & Licensure
TX State Medical License 2009 - 2028
AZ State Medical License 2012 - 2027
SC State Medical License 2023 - 2027
CA State Medical License 2012 - 2021
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification PowerChart (Clinical), Cerner Corporation, 2014-2017
- CMS Meaningful Use Stage 1 Certification FirstNet, Cerner Corporation, 2014-2017
- CMS Meaningful Use Stage 2 Certification FirstNet (Clinical), Cerner Corporation, 2014-2017
Clinical Trials
- Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients With High-Grade Upper Tract Urothelial Carcinoma Start of enrollment: 2010 Dec 14
- Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Start of enrollment: 2013 May 16
- Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal Cell Carcinoma Start of enrollment: 2013 Mar 08
Publications & Presentations
PubMed
- SETD2 Deficiency Drives Mitochondrial DNA Leakage and Creates a Druggable Dependency on BCL-xL in Clear Cell Renal Cell Carcinoma.Anusha Uprety, Chandler Judd, Emily D Villella, Rebecca Keller, Ryan Wagner
Cancer Research. 2026-08-04 - 2 citationsDevelopment of tandem antigen capture ELISAs measuring QSOX1 isoforms in plasma and serum.Calvin Koelbel, Yvette Ruiz, Zijian Wan, Shaopeng Wang, Thai Ho
Free Radical Biology & Medicine. 2024-01-01 - 11 citationsSETD2 loss in renal epithelial cells drives epithelial-to-mesenchymal transition in a TGF-β-independent manner.Tianchu Wang, Ryan T Wagner, Ryan A Hlady, Xiaoyu Pan, Xia Zhao
Molecular Oncology. 2024-01-01
Grant Support
- Synthetic Lethal Targeting of SETD2 in Renal Cell CarcinomaMAYO CLINIC ROCHESTER2023–2028
- Synthetic Lethal Targeting of SETD2 in Renal Cell CarcinomaMAYO CLINIC ROCHESTER2023–2028
- Synthetic Lethal Targeting of SETD2 in Renal Cell CarcinomaNIH-NCI2023–2028
- Deciphering the Interplay Between H3K36 and DNA Methylation in Renal CancerNIH-NCI2018–2023
- Reprogramming Chromatin Modifiers in Kidney CancerDepartment of Defense2017–2020
Professional Memberships
- Member
- Member
- Member
External Links
- Clinical interestshttp://www.mayoclinic.org/biographies/ho-thai-h-m-d-ph-d/bio-20055574
- Research interestshttp://www.mayo.edu/research/faculty/ho-thai-h-m-d-ph-d/bio-20001528?_ga=1.162847804.1074440646.1437538457
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: